Johnson & Johnson Faces 67,500 Lawsuits as Judge Allows Expert Testimony
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Yahoo Finance
- Litigation Progress: A federal judge ruled that plaintiffs in over 67,500 lawsuits against Johnson & Johnson regarding baby powder and talc products can present expert testimony at trial, marking a significant step towards trial proceedings.
- Scientific Evidence Review: The judge aims to reevaluate scientific evidence due to changes in federal rules and the emergence of new evidence, which could significantly impact the validity of expert testimonies and the overall case outcomes.
- Historical Verdicts Overview: Johnson & Johnson has faced jury awards as high as $4.69 billion in state court cases, highlighting the legal risks and potential financial burdens associated with talc-related litigation.
- Bankruptcy Strategy Failure: Johnson & Johnson's attempts to resolve litigation through bankruptcy were rejected three times by federal courts, resulting in the suspension of most cases and illustrating the challenges the company faces in its legal battles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 244.880
Low
190.00
Averages
218.50
High
240.00
Current: 244.880
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Data on IMAAVY in Myasthenia Gravis Treatment
- Clinical Study Results: The Phase 3 Vivacity-MG3 study shows that IMAAVY combined with standard care leads to a significant improvement in MG-ADL scores of -4.9 at 24 weeks compared to -2.7 in the placebo group, indicating its potential advantage in early-stage myasthenia gravis patients.
- Symptom Relief Effect: For patients with lower baseline symptom burden, IMAAVY plus standard care resulted in an MG-ADL score improvement of -4.5 versus -2.3 in the placebo group, further validating its efficacy in milder cases and potentially enhancing treatment options for clinicians.
- Control After Infections: Patients in the IMAAVY group maintained symptom improvements within two weeks after common infections, demonstrating the drug's ability to effectively manage symptoms during periods of heightened exacerbation risk, thus enhancing its clinical applicability.
- Innovative Research Design: The PETUNIA study will showcase how pregnancy outcome data will be collected during IMAAVY treatment, aiming to fill existing evidence gaps and support clinical decision-making, highlighting the focus on pregnant patients.
See More
Tech Giants Face Challenges and Opportunities
- Market Confidence Shaken: As competition for data center construction intensifies, tech giants like Amazon, Microsoft, and Google are experiencing declining investor confidence, leading to stock price volatility that impacts overall market performance.
- AI Investment Outlook Uncertain: Despite ongoing investments in AI by Meta and Apple, the lack of a clear profit model has led to cautious market expectations regarding their future profitability, potentially affecting their stock prices.
- Surge in Storage Chip Prices: The rising prices of storage chips are putting pressure on several tech companies, including Apple, which may hinder their profitability expectations from AI investments and affect overall financial health.
- Increased Risk of Industry Consolidation: With the emergence of new competitors like OpenAI and Anthropic, traditional tech giants face the risk of being marginalized, forcing them to reassess market strategies to maintain competitiveness.
See More
Abbott Laboratories: A Safe Harbor Stock Choice
- Dividend Growth Potential: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%; despite a slowdown in growth, its payout ratio of 41.6% suggests sustainable long-term dividend increases, providing investors with stable returns.
- Acquisition Impact Analysis: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, but in the long run, this deal positions Abbott as a leader in cancer diagnostics, likely driving future earnings and dividend growth.
- Market Valuation Advantage: Trading at a price-to-earnings ratio of 16.5, Abbott is more attractively valued compared to competitors like Johnson & Johnson, which trades above 20 times earnings, presenting a potentially better buying opportunity for investors.
- Defensive Investment Characteristics: As a blue-chip Dividend King, Abbott offers a relatively safe investment choice amid increasing market volatility, with its stable dividends and potential for capital appreciation making it an ideal candidate for long-term portfolios, especially in uncertain economic conditions.
See More
Abbott Laboratories: A Preferred Defensive Investment
- Dividend King Status: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%, and while growth has slowed, the consistent dividend increases provide reliable returns for investors over the long term.
- Acquisition-Driven Growth: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, yet this strategic move positions the company as a leader in cancer diagnostics, laying the groundwork for future growth.
- Relative Valuation Advantage: Trading at a forward P/E of 16.5 times, Abbott is valued lower than competitors like Johnson & Johnson, which trades over 20 times, highlighting its attractiveness among diversified healthcare stocks, especially during market volatility.
- Market Safe Haven: As market uncertainty rises, investors typically gravitate towards defensive dividend stocks, and Abbott, with its solid financial performance and growth potential, could serve as a safe harbor for investors, particularly in times of economic fluctuations.
See More
Winners and Losers in the AI Boom Debate
- Micron's Earnings Ignite Market Reaction: Micron's earnings report revealed over a fourfold year-over-year revenue increase and provided guidance exceeding Wall Street expectations, despite a 13% drop on Tuesday, the stock rebounded 16% on Thursday, reflecting market confidence in its long-term supply agreements.
- Apple's Price Increases: Apple announced price hikes for several MacBook and iPad models due to soaring memory and storage costs, resulting in a 6.1% drop in stock price on Thursday, marking its first formal move to pass costs to consumers and highlighting hardware bottlenecks affecting tech giants.
- Semiconductor Sector Volatility: Concerns over the sustainability of AI infrastructure funding arose after reports that OpenAI might delay its IPO, leading to a more than 5% drop in semiconductor stocks on Friday, with Micron ultimately finishing the week down 0.15%.
- Falling Oil Prices Ease Inflation Concerns: While tech stocks struggled, falling oil prices to around $69 per barrel alleviated inflation worries, boosting economically sensitive stocks and helping the Dow Jones Industrial Average achieve a modest weekly gain.
See More
Solvonis CEO Discusses Progress on Alcohol Use Disorder Treatment
- Positive PK Data: Solvonis reported encouraging pharmacokinetic (PK) data for its SVN-002 program, demonstrating that sublingual and buccal administration of esketamine provides comparable exposure levels to intranasal delivery, which is crucial for establishing the scientific bridge required by the FDA and accelerating clinical trial progress.
- Significant Market Opportunity: The alcohol use disorder treatment market in the US is estimated to be 4 to 5 times larger than the treatment-resistant depression market currently served by Spravato, with approximately 15 million American adults affected by moderate to severe alcohol use disorder, highlighting Solvonis's innovative potential and market demand in this area.
- Capital Efficiency Strategy: By utilizing the 505(b)(2) regulatory pathway, Solvonis can leverage existing data for a new indication, which not only reduces development costs but also potentially shortens timelines, enhancing the company's financial flexibility and strategic positioning.
- Next Steps: Solvonis plans to engage with the FDA to clarify the scope of the toxicology package and, following feedback, submit an IND application seeking approval for the planned Phase 2b trial, further advancing the clinical development of SVN-002.
See More
New Data on IMAAVY in Myasthenia Gravis Treatment
- Clinical Study Results: The Phase 3 Vivacity-MG3 study shows that IMAAVY combined with standard care leads to a significant improvement in MG-ADL scores of -4.9 at 24 weeks compared to -2.7 in the placebo group, indicating its potential advantage in early-stage myasthenia gravis patients.
- Symptom Relief Effect: For patients with lower baseline symptom burden, IMAAVY plus standard care resulted in an MG-ADL score improvement of -4.5 versus -2.3 in the placebo group, further validating its efficacy in milder cases and potentially enhancing treatment options for clinicians.
- Control After Infections: Patients in the IMAAVY group maintained symptom improvements within two weeks after common infections, demonstrating the drug's ability to effectively manage symptoms during periods of heightened exacerbation risk, thus enhancing its clinical applicability.
- Innovative Research Design: The PETUNIA study will showcase how pregnancy outcome data will be collected during IMAAVY treatment, aiming to fill existing evidence gaps and support clinical decision-making, highlighting the focus on pregnant patients.
See More
Tech Giants Face Challenges and Opportunities
- Market Confidence Shaken: As competition for data center construction intensifies, tech giants like Amazon, Microsoft, and Google are experiencing declining investor confidence, leading to stock price volatility that impacts overall market performance.
- AI Investment Outlook Uncertain: Despite ongoing investments in AI by Meta and Apple, the lack of a clear profit model has led to cautious market expectations regarding their future profitability, potentially affecting their stock prices.
- Surge in Storage Chip Prices: The rising prices of storage chips are putting pressure on several tech companies, including Apple, which may hinder their profitability expectations from AI investments and affect overall financial health.
- Increased Risk of Industry Consolidation: With the emergence of new competitors like OpenAI and Anthropic, traditional tech giants face the risk of being marginalized, forcing them to reassess market strategies to maintain competitiveness.
See More
Abbott Laboratories: A Safe Harbor Stock Choice
- Dividend Growth Potential: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%; despite a slowdown in growth, its payout ratio of 41.6% suggests sustainable long-term dividend increases, providing investors with stable returns.
- Acquisition Impact Analysis: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, but in the long run, this deal positions Abbott as a leader in cancer diagnostics, likely driving future earnings and dividend growth.
- Market Valuation Advantage: Trading at a price-to-earnings ratio of 16.5, Abbott is more attractively valued compared to competitors like Johnson & Johnson, which trades above 20 times earnings, presenting a potentially better buying opportunity for investors.
- Defensive Investment Characteristics: As a blue-chip Dividend King, Abbott offers a relatively safe investment choice amid increasing market volatility, with its stable dividends and potential for capital appreciation making it an ideal candidate for long-term portfolios, especially in uncertain economic conditions.
See More
Abbott Laboratories: A Preferred Defensive Investment
- Dividend King Status: Abbott Laboratories has raised its quarterly cash dividend for 55 consecutive years, currently offering a yield of approximately 2.8%, and while growth has slowed, the consistent dividend increases provide reliable returns for investors over the long term.
- Acquisition-Driven Growth: Abbott's $21 billion acquisition of Exact Sciences is expected to dilute earnings in the short term, yet this strategic move positions the company as a leader in cancer diagnostics, laying the groundwork for future growth.
- Relative Valuation Advantage: Trading at a forward P/E of 16.5 times, Abbott is valued lower than competitors like Johnson & Johnson, which trades over 20 times, highlighting its attractiveness among diversified healthcare stocks, especially during market volatility.
- Market Safe Haven: As market uncertainty rises, investors typically gravitate towards defensive dividend stocks, and Abbott, with its solid financial performance and growth potential, could serve as a safe harbor for investors, particularly in times of economic fluctuations.
See More
Winners and Losers in the AI Boom Debate
- Micron's Earnings Ignite Market Reaction: Micron's earnings report revealed over a fourfold year-over-year revenue increase and provided guidance exceeding Wall Street expectations, despite a 13% drop on Tuesday, the stock rebounded 16% on Thursday, reflecting market confidence in its long-term supply agreements.
- Apple's Price Increases: Apple announced price hikes for several MacBook and iPad models due to soaring memory and storage costs, resulting in a 6.1% drop in stock price on Thursday, marking its first formal move to pass costs to consumers and highlighting hardware bottlenecks affecting tech giants.
- Semiconductor Sector Volatility: Concerns over the sustainability of AI infrastructure funding arose after reports that OpenAI might delay its IPO, leading to a more than 5% drop in semiconductor stocks on Friday, with Micron ultimately finishing the week down 0.15%.
- Falling Oil Prices Ease Inflation Concerns: While tech stocks struggled, falling oil prices to around $69 per barrel alleviated inflation worries, boosting economically sensitive stocks and helping the Dow Jones Industrial Average achieve a modest weekly gain.
See More
Solvonis CEO Discusses Progress on Alcohol Use Disorder Treatment
- Positive PK Data: Solvonis reported encouraging pharmacokinetic (PK) data for its SVN-002 program, demonstrating that sublingual and buccal administration of esketamine provides comparable exposure levels to intranasal delivery, which is crucial for establishing the scientific bridge required by the FDA and accelerating clinical trial progress.
- Significant Market Opportunity: The alcohol use disorder treatment market in the US is estimated to be 4 to 5 times larger than the treatment-resistant depression market currently served by Spravato, with approximately 15 million American adults affected by moderate to severe alcohol use disorder, highlighting Solvonis's innovative potential and market demand in this area.
- Capital Efficiency Strategy: By utilizing the 505(b)(2) regulatory pathway, Solvonis can leverage existing data for a new indication, which not only reduces development costs but also potentially shortens timelines, enhancing the company's financial flexibility and strategic positioning.
- Next Steps: Solvonis plans to engage with the FDA to clarify the scope of the toxicology package and, following feedback, submit an IND application seeking approval for the planned Phase 2b trial, further advancing the clinical development of SVN-002.
See More
